Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 10;14:6332. doi: 10.1038/s41467-023-41828-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Cell viability of KRASG12C LUAD cells (H1792, HCC44, H23, H358 and CP435) treated with Sotorasib (Soto; 20–500 nM), Midostaurin (Mido; 0.3–1.25 μM) or both (72-h treatment; data: mean +/− SD; test: one-way ANOVA, Tukey’s adjustment). B Cell viability of KRASG12C cells (H1792, HCC44 and H358) in 3D (72-h treatment). Soto: 62.5 nM; Mido: 0.3 μM (data: mean +/− SD; test: one-way ANOVA, Tukey’s adjustment). C Representative images of H1792, HCC44 and H358 3D cultures exposed to treatments. Scale bar: 200 μm. D Effects of Soto and Mido combination on cell viability of mut KRAS patient-derived xenograft organoids (PDXOs: TP60, TP69, TP80, TP181, TP126) in 3D (72-h treatment). Soto: 62 nM; Mido: 0.3 μM (data: mean +/− SD; test: one-way ANOVA, Dunnet’s adjustment). E Percent cell viability of KRASG12C cells (H1792, HCC44, H23, H358 and CP435) treated with Soto (S), Mido (M), Tram (T), Afatinib (Afati, A) or combinations for 72 h (data: mean +/− SD; test: oneway ANOVA, Bonferroni’s adjustment). F Percent cell viability of KRASG12C cells (H1792, HCC44, and H358) grown in 3D, after 72 h treatment with Soto (S), Mido (M), Tram (T), Afati (A) or indicated combinations (data: mean +/− SD; test: one-way ANOVA, Bonferroni’s adjustment). G Representative crystal violet staining images of 10-day treatment (control: Ctrl; Soto: 12,5-62,5 nM; Mido: 50–100 nM). H Long-term effect of Soto and Mido combination on cell viability of KRASG12C cells (H1792, HCC44, H23 and H358). 10-day treatment (data: mean +/− SD; test: one-way ANOVA, Tukey’s adjustment). I Cell viability percentage of Soto-resistant (SR) H23 and H358 cells treated with indicated concentrations of Soto and Mido, individually or in combination (average of 3 experiments). J Western blot analysis of indicated proteins in H1792 and HCC44 KRASG12C cells (48-h treatments; loading control: ACTIN; exposure time: low and high). K Effects of Soto and Barasertib (Bara) combination on cell viability of mut KRAS (H1792, HCC44, H23, H358) cells (72-h treatment; Soto: 0.02 − 5 µM; Bara: 5 μM; (data: mean +/− SD; test: one-way ANOVA, Tukey’s adjustment).